OmniAb Inc. (OABI), which licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics, has had a very strong start to the year and has raised its revenue guidance for 2026.
The company's technology platform is known as the OmniAb platform, and at its core is its proprietary Biological Intelligence, which harnesses the immune systems of transgenic animals to generate optimized antibody candidates for human therapeutics.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.